27 June 2019

LGB advises RHEON LABS Ltd on oversubscribed £7 million equity capital raise

LGB Corporate Finance is pleased to announce that it has advised RHEON LABS Ltd on its oversubscribed £7 million Series A equity capital raise.  The transaction was achieved by way of a private placement. 

RHEON LABS is a London-based international advanced materials technology business focussing on energy control and impact resistance. The RHEON technology combines highly strain-rate sensitive polymers with a range of functional geometries, generative design techniques, manufacturing process know-how and garment integration expertise.

Originally developed to deliver impact protection for the body and head in extreme sports, the technology is equally applicable across a wide range of sectors. It can control energy of any magnitude and frequency – from small constant vibrations to life-threatening single impacts at ballistic speeds.

The RHEON technology platform has been developed over 15 years by Dr. Daniel Plant, the company’s founder and CTO, and is backed by a globally protected IP portfolio. Dr. Plant is a recognised world authority on the latest approaches to all forms of impact testing and helmet construction.

RHEON LABS works with leading sportswear and sports equipment brands to build custom solutions to enhance the performance, comfort and protection of their products. Existing customers include FLY Racing and RuRoc, highly innovative motorcycle and ski helmet brands respectively.

The funding will enable the accelerated commercialisation of RHEON LABS’s patented technology in Europe and North America, where it is experiencing strong growth as its technology becomes recognised as the global standard for impact resistance and energy control.

LGB Corporate Finance worked with RHEON LABS extensively on the articulation of its investment proposition and strategy for the capital raise. This included an assessment of the most appropriate pools of available capital and the likely terms attached, leading to a very successful private placement.

Stephen Bates, CEO of RHEON LABS, commented:

We are delighted to have completed this capital raise, which sees RHEON LABS exceed the target amount, on simple terms attracting a unique and prestigious group of private investors.  We very much look forward to working with our new backers to capitalise on the exciting opportunities facing the company right now.

We are delighted to have completed this transaction successfully and to have advised such a compelling high growth company on a landmark transaction. The deal underlines our strategic corporate finance advisory proposition and ability to access capital.

Recent Articles

7 September 2020

Back British biotech by improving the clinical trials process

Andrew Boyle, CEO of LGB & Co. Limited, wrote an article for Pharmiweb on how to improve the British biotech sector.

Read more

News & Insights

1 September 2020

Is it safe to get back in the water? SME credit investments in the post-Covid world

Please join us to hear from our expert panel on how investors are viewing the market and assessing SME risk and resilience over the next 6 months and beyond. Read more

News & Insights

27 August 2020

COVID-19 is causing a renaissance in the UK biotech sector, we must ensure it lasts

Andrew Boyle, CEO of LGB & Co. Limited, wrote an article published in PharmaPhorum on the impact COVID-19 is having on the biotech sector in the UK.

Read more

News & Insights